2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children by Lazarus, John et al.
Available at:
http://hdl.handle.net/2078.1/161279
[Downloaded 2019/04/19 at 05:16:44 ]
"2014 European thyroid association guidelines for the management
of subclinical hypothyroidism in pregnancy and in children"
Lazarus, John ; Brown, Rosalind S ; Daumerie, Chantal ;
Hubalewska-Dydejczyk, Alicja ; Negro, Roberto ; Vaidya, Bijay
Abstract
This guideline has been produced as the official statement of the European
Thyroid Association guideline committee. Subclinical hypothyroidism (SCH) in
pregnancy is defined as a thyroid-stimulating hormone (TSH) level above the
pregnancy-related reference range with a normal serum thyroxine concentration.
Isolated hypothyroxinaemia (defined as a thyroxine level below the 2.5th centile
of the pregnancy-related reference range with a normal TSH level) is also
recognized in pregnancy. In the majority of SCH the cause is autoimmune
thyroiditis but may also be due to iodine deficiency. The cause of isolated
hypothyroxinaemia is usually not apparent, but iodine deficiency may be a factor.
SCH and isolated hypothyroxinaemia are both associated with adverse obstetric
outcomes. Levothyroxine therapy may ameliorate some of these with SCH but
not in isolated hypothyroxinaemia. SCH and isolated hypothyroxinaemia are both
associated with neuro-intellectual impairment of the child, but there is no...
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there is no evidence that maternal levothyroxine therapy im-
proves this outcome. Targeted antenatal screening for thy-
roid function will miss a substantial percentage of women 
with thyroid dysfunction. In children SCH (serum TSH con-
centration >5.5–10 mU/l) normalizes in >70% and persists in 
the majority of the remaining patients over the subsequent 
5 years, but rarely worsens. There is a lack of studies examin-
ing the impact of SCH on the neuropsychological develop-
ment of children under the age of 3 years. In older children, 
the evidence for an association between SCH and impaired 
neuropsychological development is inconsistent. Good qual-
ity studies examining the effect of treatment of SCH in chil-
dren are lacking.  © 2014 European Thyroid Association
Published by S. Karger AG, Basel 
 Introduction 
 Subclinical hypothyroidism (SCH) in pregnancy is de-
fined by a serum thyroid-stimulating hormone (TSH) 
concentration higher than the upper limit of the pregnan-
cy-related reference range associated with a normal se-
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 Abstract 
 This guideline has been produced as the official statement 
of the European Thyroid Association guideline committee. 
Subclinical hypothyroidism (SCH) in pregnancy is defined as 
a thyroid-stimulating hormone (TSH) level above the preg-
nancy-related reference range with a normal serum thyrox-
ine concentration. Isolated hypothyroxinaemia (defined as a 
thyroxine level below the 2.5th centile of the pregnancy-re-
lated reference range with a normal TSH level) is also recog-
nized in pregnancy. In the majority of SCH the cause is auto-
immune thyroiditis but may also be due to iodine deficiency. 
The cause of isolated hypothyroxinaemia is usually not ap-
parent, but iodine deficiency may be a factor. SCH and iso-
lated hypothyroxinaemia are both associated with adverse 
obstetric outcomes. Levothyroxine therapy may ameliorate 
some of these with SCH but not in isolated hypothyroxin-
aemia. SCH and isolated hypothyroxinaemia are both associ-
ated with neuro-intellectual impairment of the child, but 
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rum thyroxine [T 4 ; either total (TT 4 ) or free (FT 4 )] con-
centration. The serum tri-iodothyronine (T 3 ) level is nor-
mal. It occurs in approximately 2–2.5% of pregnant 
women  [1] , although in China the incidence has been re-
ported to be 4.0%  [2] , in Belgium 6.8%  [3] and in North-
ern Spain as high as 13.7%  [4]. This is in contrast to overt 
hypothyroidism (defined as FT 4 below normal in con-
junction with elevated TSH or TSH higher than 10 mU/l 
irrespective of FT 4 levels) which has a prevalence of 
around 0.2–0.5% in pregnancy and which will not be con-
sidered further in this guideline. In children the preva-
lence of SCH is less than 2%  [5] . When considering SCH, 
it was agreed that the so-called isolated hypothyroxin-
aemia as a separate entity should also be included in the 
discussion. This is normally defined as a serum T 4 con-
centration (TT 4 or FT 4 ) as being in the lower 2.5% of the 
reference range  [6] . This definition implies that hypothy-
roxinaemia is associated with a normal TSH concentra-
tion.
 During the last 2 decades advances in our understand-
ing of thyroid physiology in pregnancy have led to the 
appreciation of the adverse effects of SCH on both the 
mother and child. Furthermore, considerable variation in 
the management of SCH in pregnancy was observed in a 
recent European Thyroid Association survey  [7] . Hence 
the European Thyroid Association commissioned a task 
force to prepare the current guidelines. In addition, there 
have never been any published guidelines on SCH in chil-
dren. The present guideline may usefully be read in con-
junction with guidelines on the management of SCH in 
non-pregnant persons recently published by Pearce et al. 
 [8] in addition to published guidelines of the American 
Thyroid Association  [6] and the American Endocrine So-
ciety  [9] both addressing the subject of thyroid and preg-
nancy.
 Methods 
 The executive committee of the European Thyroid Association 
and the guideline board nominated a task force for the develop-
ment of guidelines on the management of SCH in pregnancy and 
children. The task force had no commercial support, and the mem-
bers declared no conflict of interest. A list of all relevant topics re-
lated to SCH in pregnancy and children was created, and the mem-
bers then performed a comprehensive literature review, carrying 
out a systematic Pubmed and Medline search for original and re-
view articles published from 1970 to December 2013. The search 
terms used were TSH, levothyroxine, pregnancy, SCH, adverse ef-
fects, abortion, miscarriage, iodine, thyroid antibodies, children 
and Hashimoto’s disease. The guidelines were constructed based 
on the best scientific evidence and the skills of the task force. 
Where available, data derived from randomized clinical trials 
(RCT) rather than observational studies has been selected for rec-
ommendations. The GRADE system is employed which has been 
used in other guidelines. The quality of the literature concerning 
each aspect of the statement was graded as high (RCT evidence – 
level 1), moderate (intervention short of RCT or large observa-
tional studies – level 2) or low quality (case series, case reports, 
expert opinion – level 3) using modified GRADE criteria  [10, 11] . 
The strength of each statement was classified as strong (S, a recom-
mendation) or weak (W, a suggestion; see Recommendations be-
low), depending upon the clinical significance and weight of opin-
ion favouring the statement. Strong recommendations are clini-
cally important best practice and should be applied to most patients 
in most circumstances. In contrast, weak statements should be 
considered by the clinician and will be applicable best practice only 
to certain patients or under certain circumstances. 
 Diagnosis of SCH in Pregnancy 
 SCH can only be diagnosed on the basis of laboratory 
test results as the symptoms of both SCH and hypothy-
roidism are non-specific and mimic symptoms that can 
be associated with variations in lifestyle or those of many 
other conditions, like pregnancy itself  [12] .
 The diagnosis of primary hypothyroidism during 
pregnancy is based upon finding of an elevated serum 
TSH concentration, defined using trimester-specific TSH 
reference ranges for pregnant women. The reference in-
terval of thyroid function tests in pregnant women differs 
from that of the general population and among trimesters 
in the same patient. As the median TSH level is lower in 
the first trimester of pregnancy when compared with the 
non-pregnant reference range, the implementation of tri-
mester-specific reference ranges is recommended in or-
der to avoid misclassification of thyroid dysfunction dur-
ing pregnancy  [13] . 
 In areas with sufficient daily iodine intake, the mater-
nal thyroid is stimulated in the first trimester by human 
chorionic gonadotrophin. The inverse relationship of hu-
man chorionic gonadotrophin and TSH levels during 
early pregnancy has been extensively documented and is 
particularly evident in the subgroup of women with TSH 
values at lower centiles  [14] .
 On the base of published studies, mostly from western 
countries, either the guidelines sponsored by the Ameri-
can Thyroid Association or by the American Endocrine 
Society suggested the following reference range: first tri-
mester, 0.1 to 2.5 mU/l; second trimester, 0.2 to 3.0 mU/l; 
third trimester, 0.3 to 3.0–3.5 mU/l  [6, 9, 15–17] .
 It is a matter of discussion whether these reference 
ranges should be used worldwide. Two studies from Chi-
na  [18, 19] and 1 study from India  [20] , for example, dem-
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onstrated a significantly higher TSH reference range for 
each trimester; in particular, the study by Li et al.  [19] 
showed that the Chinese population displays 0.12–5.08 
mU/l as first trimester reference range; as a consequence, 
using the suggested 0.1–2.5 mU/l as reference range, 
about 28% of the pregnant patients in China would suffer 
from hypothyroidism, versus 4% when using an ethni-
cally specific reference range  [6, 21–23] . Further data de-
rived from the 3,944 women participating in the Genera-
tion R study demonstrated that a comparison of disease 
prevalence between a population-based versus an ethnic-
ity-specific reference range changed the diagnosis for 
18% of women who were initially diagnosed as having 
abnormal thyroid function test results  [24] .
 Other than the increase mentioned above in human 
chorionic gonadotrophin and the downward shift of 
TSH, pregnancy is also characterized by an increased io-
dine renal clearance, increased serum T 4 -binding globu-
lin, and inner-ring deiodination of T 3 and T 4 by the pla-
centa. These metabolic changes may also influence the T 4 
concentration that appears to be increased during the 
first trimester and relatively decreased during the second 
and the third trimesters. Despite the increase in T 4 -bind-
ing globulin and the decrease in albumin concentration, 
some authors maintain that the reliability of the standard 
immunoassay for FT 4 is satisfactory  [25] while others as-
sert its unreliability and emphasize the measurement of 
FT 4 in the dialysate or ultrafiltrate using online solid 
phase extraction liquid chromatography tandem mass 
spectrometry as gold standard  [26] . The method is ide-
ally suited for generating reliable, reproducible trimester-
specific reference ranges for FT 4 , but unfortunately, this 
assay technology is labour-intensive, technically demand-
ing, time-consuming and expensive, and it is not readily 
available in most clinical laboratories. 
 As the definition of SCH is based on elevated TSH in 
conjunction with normal FT 4 values, it would be of piv-
otal importance to establish a universally accepted FT 4 
trimester-specific reference range. Available data derived 
from the literature indicate that in the first trimester the 
lower FT 4 limit (2.5th percentile) of the reference range, 
detected by immunoassay, is around 0.80 ng/dl (10.30 
pmol/l)  [16, 17, 27, 28] . Given the uncertainty in FT 4 
measurement during pregnancy, alternative strategies 
have also been suggested. The first is that the non-preg-
nant TT 4 range (5–12 μg/dl or 50–150 nmol/l) can be 
adapted by multiplying this range by 1.5-fold  [16] . How-
ever, in many laboratories the measurement of TT 4 has 
been abandoned for a long time; also a TT 4 trimester-
specific reference range is lacking. The second is the so-
called FT 4 index that has been indicated as a reliable assay 
during pregnancy  [16] . In this latter case, it should be re-
membered that this index is a calculated ratio, based on 2 
estimates (estimate of T 3 resin uptake and immunoassay 
estimate of TT 4 ), both prone to inaccuracy; moreover, no 
trimester-specific reference intervals are available for the 
FT 4 index, and finally, the FT 4 index is rarely available 
 [24] . 
 In developing countries the most frequent cause of hy-
pothyroidism is represented by severe iodine deficiency, 
while in developed countries it is by chronic autoimmune 
thyroiditis (CAT). Thyroid auto-antibodies are detected 
in about 50% of pregnant women with SCH and in more 
than 80% with overt hypothyroidism  [29] . Hence in pa-
tients with SCH the measurement of thyroid peroxidase 
antibodies (TPOAb) is recommended to establish if the 
woman has thyroid autoimmunity  [30] . Although in the 
general population only positive TPOAb tests have been 
shown to be significantly associated with hypothyroid-
ism, the measurement of thyroglobulin antibodies (TgAb) 
should not be disregarded. In a study involving 992 un-
selected women consulting a tertiary referral centre for 
reproductive medicine, the prevalence of thyroid autoim-
munity was 16%; in 8% both types of antibodies were 
present, in 5% of women isolated positive TgAb were 
found and 4% had isolated positive TPOAb; women with 
isolated TgAb had significantly higher serum TSH levels 
compared to those in women without thyroid autoimmu-
nity  [31] . After the first trimester the test for thyroid an-
tibodies may be negative due to the immune suppression 
seen in pregnancy; in the presence of elevated TSH values 
and negative thyroid antibodies, thyroid ultrasonography 
may be helpful in detecting abnormal thyroid texture and 
subsequent diagnosis  [32] .
 Recommendations 
1  Trimester-specific reference ranges for TSH and T 4 
(total or free) should be established in each antenatal 
hospital setting. Local variations may occur. (2S) 
2  If TSH trimester-specific reference ranges are not 
available in that laboratory, the following reference 
range upper limits are recommended: first trimester, 
2.5 mU/l; second trimester, 3.0 mU/l; third trimester, 
3.5 mU/l. (2W) 
3  TT 4 and FT 4 assays are both suitable for thyroid func-
tion testing in pregnancy. (2S) 
4  TSH should be measured at the beginning of preg-
nancy if screening is performed. If TSH is elevated, 
FT 4 and TPOAb should be determined. This will en-
able SCH or overt hypothyroidism to be diagnosed, 
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in addition to identifying patients with isolated hypo-
thyroxinaemia as well as central hypothyroidism. 
(1S)  
5  In the case of elevated TSH and negative TPOAb, 
TgAb should be measured. Thyroid ultrasound may be 
performed to evaluate hypo-echogenicity or an inho-
mogeneous echo pattern. (2S) 
 The Role of Iodine in SCH 
 In pregnancy there is about a 50% increase in iodine 
requirement to achieve a dietary intake of 250 μg/day. 
This increase is due to: an increased glomerular filtration 
and renal iodine clearance as well as iodine transplacental 
transfer to the fetus, particularly in later gestation  [33] . In 
chronically iodine-deficient pregnant women, depleted 
iodine thyroid stores are not able to compensate for in-
creased demands; if deficiency is not corrected, it may 
result in goitre formation and maternal hypothyroidism 
 [34] . 
 In 2011, 393 million Europeans (44.2%), including 
pregnant women and those of child-bearing age, were es-
timated to be iodine deficient  [35] . Although the situation 
is slowly improving  [36] , inadequate iodine intake, par-
ticularly in populations at risk, may be observed even in 
high-income countries traditionally considered to be io-
dine sufficient  [35–39] . For example, assessment of the 
thyroid status of pregnant women living in Northern 
Spain revealed than only 14.4% of women in the first tri-
mester and 26.8% in the second trimester had optimal 
iodine nutrition defined as urinary iodine concentrations 
(UIC) between 150 and 249 μg/l  [4] . 
 The contribution of iodine deficiency to the incidence 
of SCH and isolated hypothyroxinaemia is variable, de-
pending at least on the degree of iodine deficiency and the 
incidence of thyroid antibodies. The latter would be as-
sociated with SCH independently of iodine deficiency. 
The Spanish study did show SCH in an iodine-deficient 
area  [4] . An elevated body mass index (BMI) increases the 
risk of isolated hypothyroxinaemia in iodine-deficient 
first trimester women  [40] , and the high prevalence of 
thyroid disorders including SCH in pregnancy in Bel-
gium has been noted  [3] .
 The deleterious effects of severe iodine deficiency on 
fetal development have been extensively studied. The in-
troduction of any form of iodine prophylaxis in such cas-
es decreases infant mortality and improves psychoneuro-
logical development. The actual adverse effects of mild to 
moderate iodine deficiency and the benefits resulting 
from its correction have been less intensively evaluated. 
However, there are data suggesting improved motor and 
cognitive function in children born to mothers with ad-
equate iodine intake, particularly if that status is achieved 
in prepregnancy or early pregnancy  [41, 42] . Iodine sup-
plementation during pregnancy (iodized salt vs. iodine 
supplements) may not influence postnatal child develop-
ment  [43] , although supplementation in areas of mild io-
dine deficiency may also be beneficial  [44] .
 Iodine prophylaxis in subclinically hypothyroid preg-
nant women has not been studied. Several observational 
studies in areas with adequate or high iodine intake sug-
gest that there is an increase in the incidence of thyroid 
autoimmunity. Moreover, intervention studies suggest 
that increased iodine intake may enhance thyroid auto-
immunity as well  [45] . However, not all studies gener-
ated the same findings, probably because of genetic, ra-
cial and environmental differences. It seems that autoim-
mune exacerbation is a transient phenomenon  [46] . 
Prevention of endemic goitre (and presumably some cas-
es of SCH) can be affected by iodine supplementation in 
pregnancy  [47] . 
 According to the WHO, pregnant and lactating wom-
en should be provided with 250 μg iodine daily  [48] . This 
may be achieved by administering iodine supplements 
containing 150–250 μg of iodine in the form of potassium 
iodide often as prenatal and pregnancy vitamin supple-
ments. Adequate iodine intake during pregnancy (250 μg 
of iodine daily) should be preferably achieved before con-
ception. In countries with successful salt iodization pro-
grammes, pregnancy-desiring women should be addi-
tionally supplemented with 50 μg of iodine  [49] . The dai-
ly intake of iodine should not exceed 500 μg. 
 Whether iodine administration will prevent SCH in 
iodine-deficient women is not clear. The data on TSH 
levels and iodine nutrition in pregnancy are conflicting. 
Some studies failed to recognize any significant relation 
between TSH and iodine status, most frequently assessed 
with UIC  [50, 51] . A positive correlation between TSH 
level and UIC has also been reported  [52] . Excessive io-
dine intake is even considered a risk factor for SCH (odds 
ratio, OR, of 6.2 for SCH in Chinese pregnant women 
with UIC >250 μg/l)  [53] ; the higher TSH levels in these 
iodine-supplemented women were attributed to the stun-
ning effect of a sudden increase in micronutrient con-
sumption in populations living in areas of mild to moder-
ate iodine deficiency. 
 In view of the changing iodine nutrition status of the 
European population, the international monitoring pro-
gramme should be conducted on a regular basis. 
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6  The daily iodine intake during pregnancy and lacta-
tion should be at least 250 μg and should not exceed 
500 μg. (1S) 
7  A sufficient iodine intake is usually provided by sup-
plementing euthyroid pregnant and lactating women 
with formulas containing 150 μg of iodine/day, ideally 
before conception. (1S)  
8  The effectiveness and side effects of iodine prophylaxis 
together with or without levothyroxine therapy in sub-
clinically hypothyroid women should be assessed. (3S) 
 Adverse Effects of SCH on Mother and Child 
 Maternal Effects 
 Overt hypothyroidism during pregnancy has been 
clearly associated with adverse events (pre-eclampsia, ges-
tational hypertension, cretinism, fetal deaths and sponta-
neous abortion)  [54] . Less clear is the association between 
obstetric complications and SCH. Studies investigating 
this issue have shown conflicting results. The evaluation 
of the influence of SCH on pregnancy outcome is cur-
rently hampered by the paucity of RCT showing that SCH 
directly or indirectly contributes to an increased rate of a 
specific complication, and that treatment with levothy-
roxine is able to reduce the rate of such complications. 
Most are studies of association and meta-analyses, whose 
results have always to be considered with caution.
 Recent reports suggest an increased risk for gestation-
al diabetes in SCH. A retrospective study in the USA ana-
lysing the medical records (by the International Classifi-
cation of Diseases-9 codes) of 223,512 singleton pregnan-
cies found an increased risk for gestational diabetes
(OR = 1.57, 99% confidence interval, CI, = 1.33–1.86) in 
patients with primary hypothyroidism  [55] ; although in 
this study no difference in the incidence of gestational 
diabetes mellitus could be detected between SCH and 
overt hypothyroidism. Another study involving 1,170 
women demonstrated that high TSH and thyroid autoim-
munity in early pregnancy were associated with a 4-fold 
increased risk for gestational diabetes and a 3-fold in-
creased risk for low-birth-weight neonates  [56] . Tudela et 
al.  [57] have shown that the higher the TSH, the higher 
the risk of developing gestational diabetes (the predicted 
percentage of gestational diabetes increased from 1.9 to 
4.9% as thyrotropin increased from 0.001 to 10 mU/l; p = 
0.001). The association between SCH and gestational dia-
betes mellitus is also supported by a recent meta-analysis 
 [58] . 
 Several studies have confirmed the association of SCH 
with pregnancy loss. Allan et al.  [29] showed that fetal 
death is significantly more frequent when TSH is higher 
than 6.0 mU/l (3.8 vs. 0.9%); Benhadi et al.  [59] reported 
a significantly higher mean TSH in women who experi-
enced child loss compared with successful pregnancies 
(1.48 vs. 1.11 mU/l), and that the incidence of child loss 
increased by 60% for every doubling in TSH concentra-
tion. A comparison of the TSH at 11–13 weeks in women 
who suffered fetal death versus those who did not found 
an increase in TSH multiple of the median (MoM; 1.133 
vs. 1.007 MoM), and a decrease in FT 4 MoM (0.958 vs. 
0.992 MoM)  [60] . Negro et al.  [61] observed a significant 
increase in miscarriage rate in TPOAb– women with first 
trimester TSH 2.5–5.0 mU/l versus <2.5 mU/l (6.1 vs. 
3.6%); SCH and thyroid autoimmunity were indepen-
dently associated with very early embryo loss in 216 wom-
en  [62] . An increased risk for miscarriage in women with 
untreated hypothyroidism compared with euthyroid 
controls (OR = 5.78, 95% CI = 2.4–14) was confirmed in 
a prospective study  [60] but not in a retrospective study 
where 240 SCH patients showed no difference in miscar-
riage rate when compared with 10,518 controls (OR = 
0.69, 95% CI = 0.10–5.0)  [63] .
 SCH is also associated with gestational hypertension 
and pre-eclampsia. A study of 68 hypothyroid women 
found that gestational hypertension was significantly 
more common in both overt hypothyroidism and SCH 
patients than in the general population, with rates of 22, 
15 and 7.6%, respectively  [64] . A retrospective study of 
pregnancy outcomes in 24,883 women found hyperten-
sion in pregnancy in 10.9% of SCH and 8.5% in euthyroid 
patients, with a significant association between SCH and 
severe pre-eclampsia  [65] . A meta-analysis  [66] found a 
significantly increased risk of pre-eclampsia in patients 
with SCH (OR = 1.7, 95% CI = 1.1–2.6) but no association 
between SCH and pregnancy-induced hypertension
(OR = 1.00, 95% CI = 0.79–1.29). Confirmation of an in-
creased risk of pre-eclampsia, superimposed pre-eclamp-
sia and preterm birth in primary hypothyroidism has re-
cently been obtained  [55] .
 Although positive thyroid antibodies seem to be sig-
nificantly associated with the risk of preterm delivery
(OR = 1.9, 95% CI = 1.1–3.5), this was not the case with 
SCH (OR = 1.0, 95% CI = 0.59–1.8)  [67] . A report of 404 
women with SCH showed a doubled rate of preterm birth 
with respect to controls  [67] , and a 3-fold increased rate 
of preterm deliveries in subclinically hypothyroid women 
was shown in a Chinese study of 1,000 women  [2] . A 
study involving 5,971 pregnant women showed that those 
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with a TSH >97.5th percentile had an increased risk of 
premature and very premature delivery. However, a TSH 
>97.5th centile was not associated with premature deliv-
ery or very premature delivery after the exclusion of 
TPOAb+ women or comorbidities  [68] . 
 Other complications confirmed by some and denied 
by others are placental abruption, perinatal mortality, ad-
mission to the neonatal intensive care unit, low Apgar 
score and low birth weight  [29, 56, 63, 67, 69] ; no in-
creased risk was found for high birth weight, congenital 
malformations and respiratory distress syndrome  [29, 63, 
67, 69] .
 Isolated hypothyroxinaemia (normal TSH values with 
FT 4 below the 5th centile) has been investigated in rela-
tion to adverse obstetric events. Casey et al.  [70] diag-
nosed first trimester isolated hypothyroxinaemia (FT 4 
<0.86 ng/dl) in 233/17,298 (1.3%) with no excessive ad-
verse pregnancy outcomes. In 10,990 patients first tri-
mester hypothyroxinaemia was associated with preterm 
labour (adjusted OR = 1.62; 95% CI = 1.00–2.62) and 
macrosomia (adjusted OR = 1.97; 95% CI = 1.37–2.83), 
while in the second trimester, it was associated with ges-
tational diabetes (adjusted OR = 1.7; 95% CI = 1.02–2.84) 
 [64] . The median FT 4 MoM was reduced in women with 
preterm delivery compared to control (0.94 vs. 0.99, p < 
0.001)  [60] ; in another study, isolated hypothyroxinaemia 
was related to fetal distress, small for gestational age and 
musculoskeletal malformations  [2] . Korevaar et al.  [68] 
noted that 1.4% of pregnant women were hypothyroxi-
naemic (FT 4 <2.5th percentile) and had a 2.5-fold in-
creased risk of premature delivery and a 3.6-fold in-
creased risk of very premature delivery. Similar signifi-
cant results were found when all women with low FT 4 
levels were analysed irrespective of their TSH, as well as 
after the exclusion of TPOAb+ women or those with co-
morbidities.
 Childhood Effects 
 Several studies have assessed the association between 
maternal SCH in pregnancy and neuropsychological de-
velopment of the offspring. Haddow et al.  [71] analysed 
TSH in stored sera from over 25,000 women in the second 
trimester. Sixty-two women had elevated TSH; of these, 
48 were not taking T 4 during the pregnancy. The mean 
IQ of the children born to the 48 women with high TSH 
and not on T 4 was 7 points lower than that of 124 control 
children born to women who had normal TSH levels dur-
ing the pregnancy (p = 0.005). It is noteworthy that the 
study did not classify overt hypothyroidism and SCH, 
and some of the women with high TSH had overt hypo-
thyroidism. Consistently with these results, in a prospec-
tive cohort study of 1,017 pregnant women from China, 
Su et al.  [2] found an association between SCH in early 
pregnancy (before 20 weeks of gestation) and impaired 
visual development (OR = 12.14, 95% CI = 1.22–120.70) 
and neurodevelopmental delay (OR = 10.49, 95% CI = 
1.01–119.19). A retrospective Chinese study also sup-
ports the association between maternal SCH in pregnan-
cy and impaired neuropsychological development, al-
though only 18 women with SCH were included  [72] . 
 In contrast, a recent cohort study from the Nether-
lands, which included 3,659 children and their mothers, 
did not find an association between maternal TSH in ear-
ly pregnancy and offspring cognitive development at 18 
and 30 months  [28] ; in a separate study, the same group 
did find an association between increasing maternal TSH 
in early pregnancy and behavioural problems in their off-
spring  [73] . A population-based cohort study of 1,761 
children and their mothers from Spain also failed to show 
an association between maternal TSH levels in pregnancy 
and neuropsychological development in the children 
 [74] . Another small study found a similar mean IQ in 19 
children born to women with SCH in pregnancy due to 
inadequate levothyroxine replacement and 19 control 
children whose mothers were euthyroid  [75] .
 Several studies, but not all, have also shown an asso-
ciation between maternal hypothyroxinaemia and im-
paired neuropsychological development of the offspring. 
Pop et al.  [76, 77] found that children born to women with 
FT 4 below the 10th percentile in early pregnancy have 
impaired psychomotor development. This association 
between maternal hypothyroxinaemia and impaired neu-
ropsychological development of the offspring is support-
ed by further case-control and population-based cohort 
studies  [28, 74, 78–80] . Furthermore, maternal hypothy-
roxinaemia has also been shown to be associated with at-
tention-deficit/hyperactivity disorders  [81] and autism in 
children  [82] . In contrast, other studies have failed to 
confirm the association between maternal hypothyroxin-
aemia and neuropsychological development of the off-
spring  [83–85] .  
 Conclusions 
 • Current data indicate an increase in pregnancy loss, 
gestational diabetes, gestational hypertension, pre-ec-
lampsia and preterm delivery in women with SCH in 
pregnancy. 
 • The association between SCH in pregnancy and im-
paired neuropsychological development of the off-
spring is inconsistent. 
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 • Maternal hypothyroxinaemia is associated with im-
paired neuropsychological development of the off-
spring. 
 Recommendation 
9  Further studies are required to determine the precise 
effects of SCH on obstetric outcome in addition to 
their effects on childhood neuro-intellectual develop-
ment. (2S) 
 Effects of Treatment of SCH and IH with 
Levothyroxine 
 The debate about substitution therapy in SCH is still 
open both for non-pregnant and pregnant patients. The 
background of this debate relates to association studies 
which show detrimental effects of SCH on the course of 
pregnancy and on the IQ of children born from hypothy-
roid mothers. Since results on cognitive testing of chil-
dren <3 years of age do not predict future development, 
long-term data are needed.
 A prospective, randomized trial of 984 unselected 
women with first trimester TSH of 0.3–4.2 mU/l, admit-
tedly not subclinically hypothyroid, demonstrated that 
TPOAb+ patients treated with levothyroxine had a mis-
carriage rate lower than untreated ones (3.5 vs. 13.8%), 
and similar to that of TPOAb– ones (2.4%)  [86] . A sig-
nificant increase in preterm deliveries in TPOAb+ wom-
en was also reduced in TPOAb+ patients treated with le-
vothyroxine  [86] . As patients with thyroid antibodies are 
more likely to develop SCH during gestation, this study is 
relevant to a possible therapy of SCH. A randomized con-
trol trial has shown that levothyroxine treatment de-
creased the occurrence of adverse events in the mother 
and fetus in women who were TPOAb+ and who had a 
circulating baseline TSH level >2.5 mU/l during the first 
trimester of pregnancy  [69] . A recent prospective study 
from Belgium found the same reduction in miscarriage 
rate when treating TPOAb+ women with TSH >1 mU/l 
with 50 μg of levothyroxine  [87] . 
 To date, only 1 single prospective RCT has assessed the 
effect of levothyroxine therapy for mild maternal thyroid 
failure during pregnancy on offspring IQ. Lazarus et al. 
 [88] randomized mildly hypothyroid pregnant women to 
levothyroxine treatment versus no treatment. At the age 
of 3, children of women treated with levothyroxine (start-
ed at a median gestational age of 13 weeks) had IQ tests 
which did not differ from the children of untreated wom-
en.
 Levothyroxine treatment of SCH would appear to have 
the potential benefits which outweigh the potential risks. 
The question as to whether levothyroxine therapy is indi-
cated for euthyroid women with positive thyroid anti-
bodies is beyond the scope of this guideline.
 Several ongoing studies will tell us whether or not the 
suggestion of treating SCH is definitive. A large-scale 
prospective randomized controlled trial sponsored by 
the National Institute of Child Health and Human De-
velopment (USA) is screening pregnant women with 
less than 20 weeks gestation for SCH or hypothyroxin-
aemia, and randomizing to treatment with levothyrox-
ine or placebo until delivery. The offspring will have an-
nual developmental testing done until 5 years old to de-
termine if therapy is effective in improving IQ at 5 years 
of age. The TABLET (Thyroid Antibodies and Levothy-
roxine) trial (UK), and the T 4 Life trial (the Nether-
lands), are two multicentre, placebo-controlled, double-
blind studies, designed to assess the impact of levothy-
roxine treatment (started before conception) on 
miscarriage and preterm delivery in euthyroid women 
with thyroid antibodies and investigate multiple immu-
nological markers.
 Meanwhile it is reasonable practice to maintain TSH 
values in women planning pregnancy below 2.5 mU/l, es-
pecially in those with positive TPOAb; newly diagnosed 
patients should be treated in order to normalize maternal 
serum TSH values within the trimester-specific pregnan-
cy reference range  [89] .
 Despite the pivotal role of T 4 in the neurodevelopment 
of the fetus, there is no demonstrable effect of maternal 
levothyroxine treatment on child neurodevelopment in 
relation to maternal SCH or maternal hypothyroxin-
aemia.
 Recommendations 
10  SCH arising before conception or during gestation 
should be treated with levothyroxine. (2S) 
11  To date, no study of intervention is available to dem-
onstrate a benefit from treating hypothyroxinaemic 
women in terms of obstetric complications. (1S) 
12  However, levothyroxine therapy may be considered in 
isolated hypothyroxinaemia detected in the first tri-
mester because of its association with neuropsycho-
logical impairment in children. (3W) 
13  Levothyroxine therapy is not recommended in isolat-
ed hypothyroxinaemia detected in the second to third 
trimester. (3S) 
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 Practical Management of SCH in Pregnancy 
 In a hypothyroid patient on substitutive treatment be-
fore conception, a 25–50% increase in levothyroxine dos-
age is required. The amount of levothyroxine increase de-
pends on the aetiology of hypothyroidism, being higher 
in those with radioiodine- or surgery-induced hypothy-
roidism  [90, 91] . When hypothyroidism is newly discov-
ered during pregnancy, a study suggests initiating the 
treatment with the following levothyroxine doses: 1.20 
μg/kg/day for SCH with TSH  ≤ 4.2 mU/l, 1.42 μg/kg/day 
with TSH >4.2–10 and 2.33 μg/kg/day for overt hypothy-
roidism  [92] . TSH values should be checked every 4–6 
weeks at least during the first trimester and once during 
the second and third trimesters  [93] . The recommended 
treatment of maternal hypothyroidism is with adminis-
tration of oral levothyroxine. It is strongly recommended 
not to use other thyroid preparations such as T 3 or desic-
cated thyroid, which cause lowering of serum T 4 levels. In 
patients with morning sickness, the administration of le-
vothyroxine late at night may be a valid option.
 The question arises as to what advice regarding levo-
thyroxine therapy should be given to a woman who has 
been receiving treatment during gestation for SCH. Ini-
tially, it would seem reasonable to continue levothyroxine 
therapy but adjust the dose as it will probably reduce after 
delivery. However, a recent study  [94] of 523 women 
without known thyroid disease identified 65 (12.4%) with 
SCH during pregnancy defined as TSH greater than 
3 mU/l. Of these, 75.4% had normal thyroid function 
when studied 5 years after delivery; only 16 (24.6%) had 
persistent high TSH (TSH >4.5 mU/l after pregnancy) 
suggesting that the majority of cases of SCH in pregnancy 
are transient and recover after pregnancy. Women with 
TPOAb and TSH greater than 5 mU/l in pregnancy were 
more likely to have persistently elevated TSH.
 Recommendations 
14  The recommended treatment of maternal hypothy-
roidism is administration of oral levothyroxine. The 
use of levothyroxine-T 3 combinations or desiccated 
thyroid is not recommended. (1S) 
15  The goal of levothyroxine treatment is to normalize 
maternal serum TSH values within the trimester-spe-
cific pregnancy reference range. (1S) 
16  In newly diagnosed patients with SCH in pregnancy, a 
starting dose of 1.20 μg/kg/day is advised. (2S) 
17  Women with SCH and those with overt hypothyroid-
ism desiring pregnancy should take levothyroxine in a 
dose to ensure a TSH level of <2.5 mU/l. (2S) 
18  In hypothyroid women already treated with levothy-
roxine before conception, the amount of increase in 
levothyroxine may vary from 25 to 50%, depending on 
the aetiology of hypothyroidism and prepregnancy 
TSH level. (1S) 
19  TSH values should be checked every 4–6 weeks during 
the first trimester and once during the second and 
third trimesters, and the levothyroxine dose should be 
adjusted as necessary to reduce TSH to <2.5 mU/l or 
within the trimester-specific reference range. (2S) 
20  Following delivery the levothyroxine dose should be 
reduced to the preconception dose. Women diagnosed 
with SCH during pregnancy with TSH less than 
5 mU/l and negative TPOAb could stop levothyroxine 
after delivery and have thyroid function checked 6 
weeks after delivery. (2S) 
21  Women diagnosed with SCH during pregnancy should 
be re-evaluated 6 months and 1 year after delivery to 
ascertain the continuing requirement for levothyrox-
ine. (2S) 
 Screening for Thyroid Hypofunction in Pregnancy 
 Screening is a process of identifying apparently healthy 
people who are at an increased risk of a disease or condi-
tion. They can then be offered information, further tests 
and appropriate treatment to reduce their risk and/or any 
complications arising from the disease or condition  [95] . 
Criteria for screening include the presence of a well-de-
fined medically important disorder with known inci-
dence/prevalence. The screening test should be simple 
and safe with established cut-off values, and an effective 
treatment must be available. Adequate logistics for the 
testing and follow-up must be present, and the cost of test 
relative to benefit should be known. Most importantly, 
the test should be acceptable to the patient and be ap-
proved by the hospital management  [96] .
 The universal screening of asymptomatic pregnant 
women for hypothyroidism in the first trimester is con-
troversial. Because of insufficient evidence, and because 
the criteria for universal screening are not all satisfactory, 
most professional societies essentially from iodine suffi-
cient countries recommend targeted case finding rather 
than universal screening. The American Thyroid Asso-
ciation recommends measurement of serum TSH in 
pregnant women if they are symptomatic, from an area of 
known moderate to severe iodine insufficiency, or have a 
family or personal history of thyroid disease, type 1 dia-
betes, history of miscarriage, preterm delivery, history of 
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head and neck radiation or morbid obesity (BMI >40)  [6] . 
In the American Endocrine Society guidelines some 
members recommended screening while others did not 
 [9] . All current recommendations support a targeted 
screening strategy, but such a strategy may miss at least 
from 33 to 81% of women with hypothyroidism  [97–100] .
 Therefore some endocrinologists have argued for uni-
versal screening for thyroid dysfunction in pregnant 
women or those planning to become pregnant  [29, 97] . 
However, the only prospective randomized trial under-
taken to assess the value of screening in relation to child-
hood cognitive functional outcome failed to show any 
benefit of screening in pregnancy  [88] . Nevertheless, 
there is support for screening to prevent pregnancy-asso-
ciated problems  [29, 99, 101] in addition to recognition 
of post-partum thyroiditis  [102] . Despite finding no sig-
nificant decrease in obstetric complications with univer-
sal screening and case finding, Negro et al.  [69] showed 
fewer obstetric complications in the low risk group iden-
tified by universal screening and benefiting from hypo/
hyperthyroidism treatment. This provides some evidence 
for universal screening in pregnant women with mea-
surement of TPOAb and TSH. The potential benefit of 
early thyroid screening was highlighted by a study in 
which levothyroxine treatment for TPOAb+ pregnant 
women who were diagnosed via universal screening led 
to a reduction in miscarriage rates  [87] . Moreover, a study 
evaluating the cost-effectiveness of screening all pregnant 
women for autoimmune thyroid disease during the first 
trimester demonstrated a positive cost-benefit compared 
to no screening  [103] . A meta-analysis performed by ob-
stetricians in the Netherlands concluded that the overall 
lack of evidence precludes a recommendation for univer-
sal screening and is only justified in a research setting 
 [104] . Despite a lack of consensus among professional or-
ganization guidelines regarding thyroid dysfunction 
screening, a survey conducted in Maine showed that 
many practitioners have already implemented routine 
TSH testing in pregnant women  [105] . Recently, a Euro-
pean survey found similar results, with 42% of responders 
screening all pregnant women for thyroid dysfunction 
 [7] . Results in abstracts presented at the American Thy-
roid Association meeting in October 2013 showed that 
74% of respondents advocated universal thyroid screen-
ing with TSH  [106] . The Spanish endocrine community 
also favours universal screening  [107] . To date there is 
limited evidence that levothyroxine treatment of preg-
nant women with SCH, isolated hypothyroxinaemia or 
thyroid autoimmunity is beneficial. Therefore, there is 
ongoing debate regarding the need for universal screen-
ing for thyroid dysfunction during pregnancy  [108] . Ef-
forts are still required to provide more high-quality evi-
dence to justify screening. The results of a large random-
ized study in the USA are awaited. There is some evidence 
that screening (with levothyroxine intervention therapy) 
may at least prevent or reduce some obstetric complica-
tions associated with SCH in pregnancy  [109] . There is 
also a view that it may be preferable to screen for overt 
thyroid dysfunction only  [110] . Meanwhile, optimal co-
operation and communication between endocrinologists 
and obstetricians is also necessary.
 Conclusions 
 • Evidence for screening for SCH in pregnancy is equiv-
ocal. 
 • The decision regarding screening for SCH must be re-
considered when new high-quality evidence becomes 
available. 
 • There is no evidence that screening specifically for iso-
lated hypothyroxinaemia is indicated. 
 Recommendations 
22  Despite the beneficial effects of levothyroxine treat-
ment on obstetric outcome and the fact that the previ-
ously recommended targeted approach to screening 
thyroid function will miss a large percentage of women 
with thyroid dysfunction, we do not recommend uni-
versal screening for SCH because of the lack of grade 
1 evidence. (2S) 
23  Note: although there are still no well-controlled stud-
ies to justify universal screening, the majority of the 
authors (C.D., A.H.-D., J.L., R.N.) recommend univer-
sal screening because of the beneficial effects of levo-
thyroxine treatment on unknown overt hypothyroid-
ism, on obstetric outcome and the fact that the target-
ed approach will miss a large percentage of women 
with SCH, especially in mildly iodine-deficient wom-
en. (2W) 
 SCH in Childhood 
 Diagnosis and Causes of SCH in Children 
 Dynamic changes in thyroid function occur following 
delivery in the newborn infant, but a serum TSH concen-
tration >5 mU/l can be considered to be abnormal after 1 
month of age when modern third-generation assays are 
used  [111, 112] . Thereafter, both the serum TSH and thy-
roid hormone levels continue to decline gradually to val-
ues more typical of the adult. Because the serum FT 4 con-
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centration is somewhat higher in the young, optimally 
age-related normative values for the assay in use should 
be employed, though these are not always available. The 
definition of SCH varies widely among different studies, 
with some restricting the definition to a slightly elevated 
value using a serum TSH concentration (e.g. anywhere 
between 5 and 10 mU/l), associated with an age-appro-
priate normal TT 4 or FT 4 concentration, whereas others 
use a much less stringent definition without any upper 
TSH limit.
 In addition to normative values, infants and children 
differ from adults in the causes and, therefore, the natural 
history of the thyroid dysfunction, as well as the conse-
quences. Unique to infancy and childhood, thyroid hor-
mone has important, age-dependent maturational effects 
on brain development, especially in the first 3 years of life, 
whereas effects on linear growth persist until epiphyseal 
closure in adolescence  [113] . The thyroid gland in infan-
cy and childhood is also particularly susceptible to the ef-
fects of ionizing radiation  [114, 115] . Clearly a decision 
about whether or not to treat a child with SCH will de-
pend not only on the potential for adverse effects but also 
on the likelihood that the SCH will worsen. In general, in 
iodine-sufficient areas of the world SCH in younger chil-
dren is more likely to be idiopathic or related to a diverse 
array of perinatal and genetic causes, whereas thyroid au-
toimmunity is increasingly common in older children 
and adolescents. 
 Natural History of SCH in Childhood and Adolescence 
 General Population 
 Lazar et al.  [116] reported the outcome of mild TSH 
elevation in 121,052 children in a single health care orga-
nization in Israel in whom thyroid function tests were 
ordered. Of 2.9% of children in whom the initial serum 
TSH concentration was >5.5–10 mU/l, the subsequent 
value obtained an average of 2 months later was normal 
in 73.6% and mildly abnormal in approximately 20%, 
with a tendency to normalize in those who were retested 
over the subsequent 5 years. If the initial serum TSH con-
centration was >10 mU/l, subsequent normalization was 
observed in only 40% of patients. Those whose initial se-
rum TSH concentration was >5.5–10 mU/l, 8.5% were 
treated, though the reasons for therapy were not defined. 
Antithyroid antibodies were measured in just 20% of the 
patients, and further clinical information was not avail-
able. The only predictive factors of likelihood to progress 
were an initial serum TSH concentration >7.5 mU/l and 
female gender, but not the age of the patient.
 ‘Persistent Hyperthyrotropinaemia’ and 
Non-Autoimmune (‘Idiopathic’) SCH 
 A mild elevation in the serum TSH concentration on 
newborn screening has been detected with increased fre-
quency in recent years  [117] , due, in part, to the increased 
stringency of the criteria used for diagnosis of congenital 
hypothyroidism  [118, 119] . The finding is more common 
in children born premature  [120] , small for gestational 
age  [121] and after in vitro fertilization  [122] as well as in 
those with trisomy 21  [123] . In a small proportion of cas-
es a mild morphological abnormality in thyroid gland de-
velopment  [124] or genetic defect in thyroid hormono-
genesis has been demonstrated, the latter including muta-
tions in the genes for the TSH receptor  [124–126] , dual 
oxidase 2  [127] and thyroid peroxidase  [124] . While 
many such cases represent transient abnormalities, in a 
proportion of cases the SCH persists.
 A study identified 16 cases of ‘transient hyperthyrotro-
pinaemia’ amongst 281,468 Japanese newborn babies 
screened, an incidence of 1 in 17,600  [128] . Transient hy-
perthyrotropinaemia was defined as an initial serum TSH 
concentration >4 standard deviations above the normal 
mean (equivalent to >17 mU/l, mean value 7.4 mU/l). The 
FT 4 concentration was normal in all the children studied, 
and none of the babies had an abnormality of thyroid 
gland development on imaging or heterophile antibodies 
that might have interfered with the assay for TSH. After 
2–7 years of follow-up, the serum TSH concentration 
normalized in 14 cases, and worsened in 2 despite an ini-
tial normalization within the first year of life. Three of the 
children developed a goitre.
 Daliva et al.  [129] studied 14 American infants with 
mild hypothyroidism detected on newborn screening. 
Whereas the initial filter paper T 4 concentration was ab-
normal in 2 cases, the confirmatory serum FT 4 or T 4 con-
centration was normal in 13 babies, associated with a me-
dian serum TSH level of 8.4 mU/l (normal <4.6 mU/l). All 
14 babies were treated, and thyroid hormone replace-
ment was withdrawn when the babies were approximate-
ly 3 years of age. On retesting 1–6 months later, the serum 
TSH concentration normalized in 5 of the babies and re-
mained mildly abnormal (5–11 mU/l) in 9.
 A study of 56 children with a ‘false-positive’ result on 
newborn screening found that 50% had SCH at 16–44 
months of age  [124] . In a follow-up study of 44 of these 
children at an average age of 5.3 years (range 4.1–6.6), 
SCH persisted in 19 (43.2%)  [130] . Children who were 
euthyroid in early childhood remained euthyroid on re-
evaluation, though the mean TSH concentration was sig-
nificantly higher than that of the control group. At 8 years 
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of age, SCH persisted in 14 (31.8%), in 13 of whom a mor-
phological or genetic defect could be demonstrated. None 
of the children developed overt hypothyroidism.
 Wasniewska et al.  [131] prospectively evaluated 92 pa-
tients (mean age 8.1 ± 3 years) with idiopathic SCH, de-
fined as a serum TSH concentration of 5–10 mU/l, associ-
ated with a normal T 4 /FT 4 concentration, discovered on 
routine screening. None of the patients had a history of 
thyroid irradiation or were on medication known to af-
fect thyroid function, and none had thyroid antibodies 
detectable in serum or a morphological abnormality of 
the thyroid gland either on physical examination or on 
ultrasound. After 2 years’ observation, the serum TSH 
concentration normalized in 38 patients (41%), remained 
mildly elevated in 43 (47%) and rose to >10 mU/l in 11 
(12%) in 2 of whom the TSH increase was accompanied 
by the detection of TPOAb and findings on thyroid ultra-
sound consistent with CAT.
 Trisomy 21 (Down Syndrome) 
 SCH is particularly common in children with trisomy 
21, the prevalence being estimated as between 25.3 and 
60% [for a review, see  123] . In infants and young children 
this appears to be due to a poorly understood dysregula-
tion of the hypothalamic-pituitary-thyroid axis which 
tends to normalize in a majority of patients. In 1 recent 
study of 53 children with trisomy 21 six months to 5 years 
of age, the SCH normalized in >70%, with a higher remis-
sion rate in patients without a goitre and without detect-
able thyroid antibodies in serum  [132] . In older children 
and adults, there is an increased risk of CAT (see below).
 Chronic Autoimmune Thyroiditis  
 In older children and adolescents, the most frequent 
cause of SCH is CAT, a disorder that is more common in 
certain genetic syndromes (trisomy 21 and Turner syn-
drome) and in patients with other organ-specific autoim-
mune diseases (especially type 1 diabetes and coeliac dis-
ease)  [133] . 
 SCH due to CAT is commonly thought to be benign 
and remitting in childhood, but analysis of the data is 
complicated by differences between studies in patient se-
lection, small numbers and a relatively limited duration 
of follow-up. We evaluated the results of 7 observational 
studies in different ethnic populations in which the num-
ber of subjects was >10 and the follow-up was  ≥ 2 years 
 [134–140] . Overall, of 250 children evaluated for an aver-
age duration of 4.3 years, 33.9% became euthyroid; in 
41.7% SCH persisted while in 24.4% of children the hy-
pothyroidism worsened. However, the results were heav-
ily influenced by the definition of SCH. We therefore 
stratified studies according to whether the initial mean 
serum TSH concentration was  ≤ 20 or  ≤ 12 mU/l ( table 1 ). 















↑TSH /OH SCH euthyroid
Initial TSH ≤20 mU/l
Moore [134] R USA 18 (7) 19.1 (5.2 – 64) 0.6 – 5.0 5.8 (1 – 1.8) 1 (5.6) 10 (55.6) 7 (38.9)
Wang et al. [135] P Taiwan 15 >5–<20 >5 6.4 ± 3.9 4 (26.7) 3 (20) 8 (53.3)
Gopalakrishnan et al. [136] P India 32 10.95 (6.8 – 18.7) 0.25 – 5.0 >2 4 (12.5) 21 (65.6) 7 (21.9)
Fava et al. [137] R/P Italy 14 9.3 ± 3.7 <5.0 4.7(2.8 – 12.4) 1 (7.1) 10 (71.4) 3 (21.4)
Subtotal 79 ≤20 4.7 10 (12.9) 44 (53.2) 25 (33.9)
Initial TSH ≤12 mU/l
Radetti et al. [138] Italy 55 >8.8 – 10 <4.2 – 5.0 4.9 (0.1 – 32.6) 23 (41.8) 16 (29.1) 16 (29.1)
Demirbilek et al. [139] R/P Turkey 29 8.0 (6.2 – 11.6) n.a. 3.4 (1.8 – 6) 11 (37.9) 9 (31) 9 (31)
Radetti et al. [140] R Italy 87 >8.8 – 10 <4.2 – 5.0 3 34 (39.1) 17 (19.5) 36 (41.4)
Subtotal 171 ≤12 3.8 68 (39.8) 42 (24.6) 61 (35.7)
Total 250 4.3 78 (31.2) 86 (34.4) 86 (34.4)
Number = Number of patients, with number treated in parentheses; follow-up expressed as median with range in parentheses or 
mean ± SD; outcome given as number with percentage in parentheses. OH = Overt hypothyroidism; R = retrospective; P = prospective; 
n.a. = not assessed.
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 Whereas approximately one third of children became 
euthyroid irrespective of the definition of SCH, the hypo-
thyroidism apparently worsened in a much larger percent-
age of patients when the definition was limited to a serum 
TSH concentration <12 mU/l. Since the T 4 /FT 4 concentra-
tion was not indicated in the latter studies, some of these 
patients would not have been considered to have worsened 
in the studies in which a higher TSH cut-off was used. Pro-
gression to overt hypothyroidism was associated in some 
but not all studies with the initial TSH concentration and 
the presence of a goitre and, in one report, with the coex-
istence of coeliac disease  [140] . Elevated TgAb and TPOAb 
at diagnosis and an increase in the serum TSH and TPOAb 
concentration on follow-up were also associated with an 
increased risk of progression in some but not all studies.
 SCH after Irradiation 
 Children, particularly those <10 years of age, are espe-
cially susceptible to the development of both thyroid dys-
function and thyroid cancer following ionizing radiation, 
whether following therapeutic irradiation (e.g. for child-
hood cancer)  [141, 142] or following environmental ex-
posure (e.g. after the Chernobyl accident)  [114, 143] . Of 
these, the most common outcome is SCH. In 1 study of 
142 cancer survivors who had received irradiation during 
childhood as part of the conditioning regimen prior to 
bone marrow transplantation, SCH developed in 39 pa-
tients (26.5%) 1–10 years later  [115] . SCH was signifi-
cantly more common in those who were <9 years of age 
at the time of the irradiation than in those who were old-
er, and similar results have been obtained by others. The 
long-term history of SCH following thyroid irradiation is 
unknown, but thyroid function has been reported to im-
prove in a proportion of patients on long-term follow-up.
 Adverse Effects of SCH in Children 
 Most children with SCH do not have symptoms of 
overt hypothyroidism  [144, 145] .
 Effects of SCH on Neuropsychological Development 
 Whilst it is generally accepted that an optimum thy-
roid hormone level is critical for brain development in the 
first 3 years of life, there is lack of high-quality studies 
examining the effect of SCH on neurodevelopment in this 
patient group. However, several studies have assessed the 
association between SCH and neuropsychological devel-
opment in older children. In the National Health and Nu-
trition Examination Survey III study, 30 (1.7%) of 1,327 
adolescents aged 13–16 years were found to have SCH  [5] . 
Cognitive function, assessed using the Revised Wide 
Range Achievement Test and Revised Wechsler Intelli-
gence Scale for Children tools, in these children with SCH 
was not impaired as compared to euthyroid children in 
the study. Likewise, verbal, performance and full-scale IQ 
scores in children with SCH were normal and similar to 
those of controls  [5] . In contrast, a small study found that 
11 children with SCH performed poorly in cognitive test-
ing for attention as compared to the normative data  [146] . 
In another study with 17 cases and 17 controls, there was 
no significant difference in the total intelligence scores 
between the two groups, but children with SCH per-
formed poorly in tests measuring attention  [147] .
 Effects of SCH on Growth 
 Three observational studies have examined the asso-
ciation between SCH and short stature in children. In a 
cohort study of 88 children and adolescents with SCH, 
19.3% were found to have idiopathic short stature  [126] , 
although this high prevalence may have been due to selec-
tion bias. In contrast, a cross-sectional case-control study 
of 36 children with SCH and 36 healthy euthyroid chil-
dren matched for age, sex, puberty and socio-economic 
status did not show an association between SCH and 
short stature  [144] . Furthermore, there was no significant 
difference in height of the children whose SCH persisted 
compared to those whose SCH resolved after a follow-up 
period of 2–9.3 years. Consistent with these findings, 
there were no significant changes in height of the children 
with persistent SCH as compared to those whose thyroid 
function normalized during the 2-year study period 
 [131] .
 Effects of SCH on BMI, Metabolic Parameters and 
Cardiovascular Risk  
 The studies analysing the association between obesity 
and SCH in children have shown inconsistent results. In a 
cohort study of 88 children and adolescents with SCH, 
28.4% were found to be overweight or obese, although this 
high prevalence may be due to selection bias  [126] . How-
ever, a large community-based study has also shown a sig-
nificantly higher prevalence of SCH in obese children as 
compared to non-obese children (9 vs. 6.5%)  [148] . In an-
other large cohort study of 22,747 children and adolescents 
with type 1 diabetes, 1,638 (7.2%) were found to have SCH. 
These children had significantly higher BMI as compared 
to euthyroid children  [149] . In contrast, other studies 
failed to confirm the association between SCH and obesity 
 [131, 144] . Furthermore, as the TSH level in obese children 
tends to decrease with weight loss from lifestyle changes 
 [150–152] and levothyroxine treatment in children with 
 Lazarus  /Brown  /Daumerie  /
Hubalewska-Dydejczyk  /Negro  /Vaidya  
Eur Thyroid J 2014;3:76–94
DOI: 10.1159/000362597
88
hypothyroidism is associated with minimal change in BMI 
 [153] , it is thought that the mildly elevated TSH is the con-
sequence of obesity rather than the cause  [154] . 
 A significantly higher concentration of serum total and 
low-density lipoprotein cholesterol was found in children 
with SCH as compared to euthyroid children  [150] . Like-
wise, another large cohort study including over 12,000 
children and adolescents showed that high serum TSH 
levels are significantly associated with both systolic and 
diastolic blood pressure, and increased the risk of hyper-
tension in children (OR = 1.72, 95% CI = 1.15–2.57) but 
not in adolescents  [155] . Finally, in a small case-control 
study, 34 obese children and adolescents with SCH were 
found to have significant impairment of diastolic and lon-
gitudinal systolic cardiac function on echocardiography 
as compared to 60 obese children with normal TSH  [156] .
 Effects of SCH on Bone Health 
 A case-control study with 25 children and adolescents 
with SCH and 25 age- and sex-matched healthy controls 
showed no difference in bone mineral density and bio-
chemical markers of bone metabolism in the two groups 
 [157] . 
 Impact of Treatment of SCH in Children 
 Several studies (mostly non-randomized with small 
sample size) have examined the effects of treatment of 
SCH in children. A non-randomized study in 39 children 
(24 prepubertal and 15 pubertal) presenting with short 
stature and SCH found improvement in growth velocity 
with levothyroxine treatment for 1 year  [158] . Likewise, 
an improvement in growth velocity with levothyroxine 
replacement was also found in prepubertal children with 
type 1 diabetes and SCH  [159] . In contrast, a non-ran-
domized study using levothyroxine treatment in 69 chil-
dren with SCH (compared to untreated children with 
SCH) for 2 years showed no significant difference in BMI 
or height  [145] .
 In a small retrospective case-control study, 13 children 
with type 1 diabetes with SCH were found to have a sig-
nificantly increased frequency of symptomatic hypogly-
caemia as compared to 31 controls despite similar hae-
moglobin A 1c and total insulin requirement in the two 
groups  [160] . After levothyroxine replacement, the fre-
quency of hypoglycaemic episodes in children with SCH 
was similar to that in the controls. 
 In a secondary analysis of pooled data from 3 RCT of 
dietary iodine supplementation, correction of iodine de-
ficiency (associated with SCH) in children showed an im-
provement in several metabolic parameters, including re-
duction in serum C peptide, total cholesterol and low-
density lipoprotein cholesterol  [161] .
 A small short-term non-randomized study (with only 
11 children with SCH and 6–8 weeks of study duration) 
did not show a benefit of levothyroxine treatment in neu-
rocognitive function  [146] . 
 Conclusions 
 • In the general population, SCH (serum TSH concen-
tration >5.5–10 mU/l) normalizes in >70% of children 
and adolescents and persists in the majority of the re-
maining patients over the subsequent 5 years, but rare-
ly worsens.  
 • Non-autoimmune ‘idiopathic’ SCH, either discovered 
on newborn screening or later during childhood, is a 
heterogeneous disorder that normalizes in 58% (range 
36–88) of patients or persists, but worsens in approxi-
mately 10% after up to 8 years of follow-up. 
 • SCH is 10 times more common in Down syndrome 
than in the general population. In younger infants and 
children with negative thyroid auto-antibodies there is 
a >70% chance that thyroid function will normalize. In 
children >8 years of age and in adolescents, SCH is 
more likely to be due to CAT. 
 • In SCH due to CAT in children, thyroid function nor-
malizes in approximately 34% of patients, remains sta-
ble in 42% and worsens in 24% over 4 years of follow-
up, but there is considerable fluctuation in individual 
patients and the risk of progression depends to a con-
siderable extent on the definition of SCH.  
 • In obese patients, a serum TSH concentration between 
5 and 7 mU/l is likely to be the consequence not the 
cause of the obesity.  
 • Most children with SCH do not have symptoms and 
signs of overt hypothyroidism. 
 • There is a lack of studies examining the impact of SCH 
on neuropsychological development of children under 
the age of 3 years. In older children, the evidence for 
an association between SCH and impaired neuropsy-
chological development is inconsistent. 
 • SCH in children is not associated with adverse effects 
on growth or bone health but may be associated with 
adverse cardiovascular parameters. 
 • Good-quality studies examining the effect of treat-
ment of SCH in children are lacking. 
 Recommendations 
24  In infants >1 month of age whose serum TSH concen-
tration has failed to normalize, therapy with levothy-
roxine is recommended until 3 years of age when brain 
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development is no longer thyroid hormone depen-
dent. At that time a trial off therapy can be performed 
to determine whether the hypothyroidism was tran-
sient or is permanent. (2S) 
25  If an elevated TSH persists, thyroid imaging is recom-
mended to determine whether a structural abnormal-
ity exists and whether, therefore, the SCH is likely to 
be permanent. Further evaluation to identify a possible 
genetic abnormality of thyroid hormonogenesis is op-
tional. (1S) 
26  In children with SCH >3 years of age in whom thyroid 
auto-antibodies are negative initially, regular moni-
toring of the serum TSH and TPOAb concentration is 
indicated. Because of the low risk of progression, mon-
itoring can be performed in 1 year’s time, and less fre-
quently thereafter if no worsening is observed. (2S)  
27  Regular monitoring of thyroid function in patients 
with trisomy 21 is recommended. For further detail, 
the reader is referred to specific guidelines on this top-
ic  [162, 163] . (2S) 
28  The risk of progression to overt hypothyroidism ap-
pears to be increased in children with SCH due to CAT. 
Therefore it is suggested that in patients with an elevat-
ed TPOAb and/or TgAb concentration at presentation, 
TSH (±TPOAb) be monitored every 6–12 months. 
More frequent monitoring should be considered in pa-
tients whose initial TSH concentration is >10 mU/l in 
whom a decision has been made not to treat. (2W) 
29  The decision about whether or not to treat should be 
made after careful discussion with the parents of the 
risks and potential benefits of treatment. At present 
there is insufficient evidence to recommend treatment 
in the majority of children with SCH in whom the se-
rum TSH concentration is <10 mU/l and in whom the 
TT 4 /FT 4 concentration is normal. (2W) 
30  Although high-quality studies are lacking as to a caus-
al association of SCH after childhood thyroid irradia-
tion with thyroid cancer, it would appear reasonable to 
treat individuals in this patient group. (2W) 
 Concluding Remarks 
 A majority of recommendations of the current guide-
line on the management of SCH in pregnancy is consis-
tent with that of the previous guidelines from the Ameri-
can Thyroid Association  [6] and the Endocrine Society 
 [9] on the same topic. However, recent advances in the 
field mean that there are several noticeable differences in 
the current guideline. For example, the current guideline 
underlines the importance of ethnic variation in trimes-
ter-specific reference ranges for TSH and FT 4 , recognizes 
the utility of testing TgAb to ascertain autoimmunity as 
the aetiology of SCH in pregnancy, and recommends 
considering levothyroxine replacement in isolated mater-
nal hypothyroxinaemia in the first trimester. It also em-
phasizes the use of ultrasound in diagnosis. It is hoped 
that this guideline will promote the evidence base and 
contribute in reducing inconsistencies in clinical practice 
by defining current standards of care in the management 
of SCH in pregnancy and children. 
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